MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
0 hedge funds and large institutions have $0 invested in MyoKardia, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 236 closing their positions.
100% less funds holding
Funds holding: 237 → 0 (-237)
100% less funds holding in top 10
Funds holding in top 10: 18 → 0 (-18)
100% less capital invested
Capital invested by funds: $7.67B → $0 (-$7.67B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 236
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.08B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$747M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$602M |
| 4 |
BlackRock
New York
|
-$578M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$410M |
MYOK Hedge Fund Activity: Q4 2020 in Review
0 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q4 2020, worth a combined $0 — down 100% from $7.67B a quarter earlier.
Sellers outnumbered buyers: 236 funds closed out of MYOK and 0 opened new positions — a net loss of 236 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Fidelity Investments, exiting entirely with an estimated $1.08B sold.
- 0 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q4 2020, down from 237 in Q3 2020.
- Funds reported $0 of MyoKardia, Inc. Common Stock stock for Q4 2020, down 100% quarter-over-quarter.
- 0 funds opened new MyoKardia, Inc. Common Stock positions in Q4 2020 and 236 closed out, a net change of -236 holders.
- The largest MyoKardia, Inc. Common Stock seller in Q4 2020 was Fidelity Investments, an estimated $1.08B sold.
Based on aggregated 13F filings for Q4 2020.